Rankings
▼
Calendar
EOLS
Evolus, Inc.
$353M
Q2 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$67M
+35.6% YoY
Gross Profit
$47M
70.3% margin
Operating Income
-$8M
-11.5% margin
Net Income
-$11M
-17.0% margin
EPS (Diluted)
$-0.18
QoQ Revenue Growth
+12.8%
Cash Flow
Operating Cash Flow
-$6M
Free Cash Flow
-$8M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$234M
Total Liabilities
$214M
Stockholders' Equity
$19M
Cash & Equivalents
$94M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$67M
$49M
+35.6%
Gross Profit
$47M
$35M
+35.9%
Operating Income
-$8M
-$15M
+49.1%
Net Income
-$11M
-$18M
+37.4%
Revenue Segments
Product
$66M
99%
Service
$687,000
1%
← FY 2024
All Quarters
Q3 2024 →
EOLS Q2 2024 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena